CommercialPrior AuthHigh impact
Etanercept (CPB 0315, reviewed 2026-07-08)
Aetna·Rheumatology, Dermatology, Oncology +3 more·Medical Policy
Effective date
Jul 8, 2026
We identified it
Aug 13, 2026
Summary
Aetna has updated its Clinical Policy Bulletin 0315 for Etanercept (Enbrel) effective immediately, establishing comprehensive prior authorization criteria across multiple rheumatologic, dermatologic, and oncologic conditions. The policy specifies prescriber specialty requirements, biomarker testing mandates, prior treatment failure documentation, and disease activity thresholds that must be met before coverage approval. Billing teams must implement these authorization requirements across all affected indications to prevent claim denials.
Action Required
Immediately: Billing team must implement prior authorization workflow for all Etanercept (Enbrel) claims submitted to Aetna. REQUIREMENTS: (1) Before processing any Etanercept claim, verify the patient's diagnosis falls within covered indications (RA, JIA, PsA, AS, nr-axSpA, PsO, reactive arthritis, hidradenitis suppurativa, GVHD, Behçet's disease, or immune checkpoint inhibitor-related conditions); (2) Confirm treating provider specialty matches Aetna's requirements (e.g., rheumatologist for RA/AS, dermatologist for PsO, oncologist for checkpoint inhibitor toxicity); (3) Request and document required prior treatment history (prior biologic use within 120 days, OR failure/intolerance of specific conventional synthetic drugs per indication); (4) For RA and PsA: Obtain documentation of biomarker testing results (RF, anti-CCP, CRP/ESR for RA; documented disease activity for PsA); (5) For all diagnoses: Verify disease activity level meets policy thresholds (e.g., moderately to severely active for RA/JIA/PsA, active for AS/nr-axSpA, moderate-to-severe for PsO); (6) Update billing software rules and prior auth submission templates to reflect these new requirements; (7) Train billing and clinical staff on the specific documentation requirements for each indication. Consequences of inaction: Claims submitted without required prior authorization documentation will be denied, requiring resubmission and delaying patient access to therapy.